Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Teva Pharmaceutical Industries : Big blow for Teva as FDA approves Mylan's generic Copaxone

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 09:34pm CET

Oct. 04--In a major blow for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), pharmaceutical rival Mylan N.V. (Nasdaq: MYL; TASE: MYL) reported after close of trade last night that the US Food and Drug Administration (FDA) had approved its generic versions of Copaxone. Mylan said that the FDA had approved its 20 mg. daily injection version of the multiple sclerosis treatment and its 40 mg three times weekly version. Mylan says it can begin marketing imminently.

Copaxone is Teva's flagship branded drug. Sales reached nearly $2 billion in the first half of 2017 with estimated profits of $1.5 billion.

Copaxone's price has risen 1,002% since it was launched in 1996, and the price of the 40 mg version has risen 30% since it was launched in 2014.

In premarket trading on Wall Street, Teva's share price was down 15.25% at $15.94.

Teva warned that any launch by Mylan of a generic version of Copaxone 40mg prior to final resolution of the pending patent appeals and other patent litigation should be considered an "at-risk" launch, which could subject Mylan to significant damages among other remedies.

"We have planned for the eventual introduction of a generic competitor to glatiramer acetate," said Dr. Yitzhak Peterburg, Teva's Interim president and CEO. "We remain confident in patient and physician loyalty to Teva's Copaxone due to its recognized efficacy, safety and tolerability profile, and we will continue to promote and support the product. As we are closing the third quarter, it is too soon to officially comment on any change to our full year business outlook."

Due to the anticipated launch of another generic 20mg glatiramer acetate product and the anticipated launch of a first generic 40mg glatiramer acetate product, Teva's early assessment of the impact of these launches to its earnings for the fourth quarter ended December 31, 2017 is that it could be affected by at least $0.25 cents per share.

___

(c)2017 the Globes (Tel Aviv, Israel)

Visit the Globes (Tel Aviv, Israel) at www.globes.co.il/serveen/globes/nodeview.asp?fid=942

Distributed by Tribune Content Agency, LLC.

© Tribune Content Agency, source Regional News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
01/17 TEVA PHARMACEUTICAL INDUSTRIES : FDA approves Teva leukemia treatment
01/17 TEVA PHARMACEUTICAL INDUSTRIES : U.S. FDA Approves Tevas Trisenox
01/16 TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. FDA Approval of TRISENOX Injecti..
01/16 TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. FDA Approval of TRISENOX (arseni..
01/16 TEVA PHARMACEUTICAL INDUSTRIES : Embattled Teva fined NIS 75m. for bribing forei..
01/15 TEVA PHARMACEUTICAL INDUSTRIES : settles graft case with Israeli authorities
01/15 TEVA PHARMACEUTICAL INDUSTRIES : agrees future of Abic Netanya with workers
01/15 TEVA PHARMACEUTICAL INDUSTRIES : corruption settlement doesn't cover co officers
01/15 TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. FDA Approval of TRISENOX® (arsen..
01/14 TEVA PHARMACEUTICAL INDUSTRIES : Moody's cuts Teva debt to junk status
More news
News from SeekingAlpha
01/17 YOUR DAILY PHARMA SCOOP : Eiger Selloff, Novartis' Cosentyx, RXi Outlines Busine..
01/16 FDA OKs Teva's Trisenox for certain type of APL
01/15 UPDATE : Neos Therapeutics Seems To Be Capitalizing On Pfizer's Decisions
01/13 YOUR DAILY PHARMA SCOOP : Lipocine's Gloomy Future, Puma Labeling Change, Concer..
01/13 THE PASSIVE DGI CORE PORTFOLIO : 2017 End-Of-Year Review
Financials ($)
Sales 2017 22 633 M
EBIT 2017 6 276 M
Net income 2017 -
Debt 2017 34 419 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,52x
EV / Sales 2018 2,44x
Capitalization 22 505 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 23,3 $
Spread / Average Target 6,1%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED16.51%22 505
JOHNSON & JOHNSON4.32%394 542
NOVARTIS1.41%227 089
PFIZER0.88%218 162
ROCHE HOLDING LTD.-4.26%211 361
MERCK AND COMPANY10.31%169 287